TickerFacts.

Company research / NPHC

Nutra Pharma Corp (NPHC)

Build a valuation ↗↓ Download CSV

SEC name NUTRA PHARMA CORP · CIK 0001119643 · OTC · Medicinal Chemicals & Botanical Products

  • Sector Manufacturing
  • Incorporated CA
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Nutra Pharma Corp reported revenue of $257.6K. Revenue grew 4.6% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $160.8K.

Key ratios (year ended 2025-12-31)

76.3%
Gross margin
-567.7%
Operating margin
-794.8%
Net margin
4.6%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-09-02

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$160.8K$257.6K$246.3K$205.6K$145.8K$97.7K$51.9K$104.4K$130.6K$121.0K$168.4K
Cost of Revenuen/a$183.7K$84.8K$177.5K$162.8K$41.3Kn/an/a$68.8K$26.9K$39.0K
Gross Profitn/a$196.6K$247.3K$396.5K$249.0K$8.5K$14.9K$34.7K$14.1K$94.1K-$54.6K
Operating Income-$1.64M-$1.46M-$878.4K-$887.0K-$1.91M-$1.99M-$924.9K-$1.23M-$1.88M-$1.38M-$2.04M
Depreciation & Amortizationn/an/an/an/an/a$9.1K$3.8Kn/an/an/an/a
EBITDAn/an/an/an/an/a-$1.98M-$921.1Kn/an/an/an/a
Net Income-$5.42M-$2.05M-$1.29M-$1.39M$8.18M-$13.10M-$769.2K-$6.59M-$3.88M-$4.03M-$3.45M
EPS (Diluted)n/a$0.00$0.00$0.00$0.00$0.00n/an/an/an/an/a
Total Assets$622.9K$584.6K$599.5K$640.4K$754.9K$780.0K$301.8K$339.8K$141.4K$389.6K$214.3K
Total Liabilities$21.83M$17.41M$15.41M$14.41M$13.13M$21.66M$11.80M$12.04M$6.08M$5.80M$4.69M
Long-Term Debt$12.57M$9.76M$8.63M$8.47M$8.19Mn/a$214.8Kn/an/an/an/a
Shareholders' Equity-$21.21M-$16.83M-$14.81M-$13.77M-$12.38M-$20.88M-$11.49M-$11.70M-$5.94M-$5.41M-$4.48M
Cash & Equivalentsn/a$12.2K$36.4K$0$0n/an/an/an/an/an/a
Operating Cash Flow-$1.05M-$1.16M-$424.0K-$550.0K-$762.4K-$1.74M-$878.1K-$743.7K-$999.9K-$1.14M-$1.36M
Capital Expendituresn/a$26.1Kn/an/a$58.0K$39.0K$5.9Kn/an/a$9.1K$3.4K
Free Cash Flown/a-$1.19Mn/an/a-$820.4K-$1.78M-$884.0Kn/an/a-$1.15M-$1.36M
Shares Outstanding7.16B7.10B7.10B7.06B7.04B6.77B6.96B5.88B4.05B2.03B295.07M
Weighted Average Diluted Sharesn/a7.78B7.67B7.61B19.10B7.23Bn/an/an/an/an/a
EPS (Basic)n/a$0.00$0.00$0.00$0.00$0.00n/an/an/an/an/a